🇺🇸 FDA

Company profile · Sponsor

Eli

Eli Lilly and Company

EBA3EE7 · NMPA pharma GURGAON, CN
Pipeline
24
Drugs
0
Patents
0

Quick answer

Eli (EBA3EE7) is a pharma company. headquartered in GURGAON, CN. listed on NMPA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EBA3EE7
Exchange NMPA
Company type pharma
Headquarters GURGAON, CN

Pipeline (24)

Search pipeline →

  1. 5 mg Tadalafil

    Eli

    Benign Prostate Hyperplasia

    phase 3 small molecule completed

    1 trial

  2. Abemaciclib

    Eli

    Breast Cancer

    phase 3 small molecule active

    1 trial

  3. Abemaciclib

    Eli

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  4. Baricitinib

    Eli

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  5. Baricitinib

    Eli

    Systemic Lupus Erythematosus

    phase 3 small molecule terminated

    1 trial

  6. Clopidogrel

    Eli

    Acute Coronary Syndrome

    phase 3 small molecule completed

    1 trial

  7. Drotrecogin alfa (activated)

    Eli

    Sepsis

    phase 3 small molecule completed

    1 trial

  8. Duloxetine hydrochloride

    Eli

    Diabetic Neuropathies

    phase 3 small molecule completed

    1 trial

  9. Eloralintide

    Eli

    Obesity

    phase 3 small molecule active

    1 trial

  10. Glargine

    Eli

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  11. Human Insulin Inhalation Powder

    Eli

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  12. LY2127399

    Eli

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  13. LY2127399

    Eli

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  14. LY2216684

    Eli

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  15. Lebrikizumab

    Eli

    Atopic Dermatitis

    phase 3 mab completed

    1 trial

  16. Mirikizumab

    Eli

    Ulcerative Colitis

    phase 3 small molecule active

    2 trials

  17. Mirikizumab SC

    Eli

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  18. Necitumumab

    Eli

    Non Small Cell Lung Cancer

    phase 3 mab completed

    1 trial

  19. Orforglipron

    Eli

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  20. Orforglipron

    Eli

    Peripheral Arterial Disease

    phase 3 small molecule active

    1 trial

  21. Orforglipron

    Eli

    OSA

    phase 3 small molecule active

    1 trial

  22. Pemetrexed

    Eli

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  23. Placebo

    Eli

    Hepatocellular Carcinoma

    phase 3 mab completed

    1 trial

  24. Ramucirumab

    Eli

    Urothelial Carcinoma

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is Eli?

Eli (EBA3EE7) is a pharma company. headquartered in GURGAON, CN. listed on NMPA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Eli sponsor?

We track 24 ClinicalTrials.gov-linked programs for Eli, including 5 mg Tadalafil and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Eli company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.